CHCHD6

Across TCGA pan-cancer cohorts, CHCHD6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CHCHD6 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CHCHD6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHCHD6 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

CCRCC, HNSC, and GBM are the cancer types where CHCHD6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.221	0.849	<.001	25	view →
HNSC	DFS	Median	IV	0.503	0.785	.001	20	view →
GBM	DFS	Quartile	All	0.921	0.689	.002	7	view →
LUAD	OS	Quartile	II,III,IV	0.658	0.282	.010	6	view →
PDAC	DFS	Median	II,III,IV	0.705	0.828	.032	2	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.853	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CHCHD6–CCRCC (DFS)

Open the CCRCC breakdown →